MGMasaomi Gohbara

Masaomi Gohbara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaomi Gohbara has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intravascular ultrasound–derived calcium score to predict stent underexpansion in moderately to severely calcified lesions

    by Masaomi Gohbara, Masahiko Noguchi, Yasuhiro Nakano, Yohei Sotomi, Kouji Yamamoto, Kyoko Hattori, Shun Kitajima, Yohei Hanajima, Katsuhiko Tsutsumi, Hidekuni Kirigaya, et al.


  • Association between intimal thickness of superficial calcified sheet and calcium fracture after intravascular lithotripsy

    by Masaomi Gohbara, Shun Kitajima, Kyoko Hattori, Yohei Hanajima, Katsuhiko Tsutsumi, Hidekuni Kirigaya, Jin Kirigaya, Shinnosuke Kikuchi, Hidefumi Nakahashi, Yuichiro Kimura, et al.

    The association between intimal thickness of the superficial calcific sheet and calcium fracture after intravascular lithotripsy (IVL) during percutaneous coronary intervention (PCI) remains unclear. This study aimed to investigate the association between intimal thickness of the superficial calcific sheet and calcium fracture after IVL in PCI. Among 40 consecutive PCIs with IVL, 24 lesions from 23 PCIs in 21 patients with complete pre-IVL, post-IVL, and final post-stenting optical coherence tomography (OCT) or optical frequency domain imaging (OFDI) were analyzed. Cross sections with eruptive calcified nodules or calcified protrusions were excluded. In total, 357 cross-sectional OCT/OFDI segments of superficial calcific sheet were analyzed at 1-mm longitudinal intervals. Maximum intimal thickness was defined as the thickest intima of the superficial calcific sheet. Segments with calcium fracture after IVL had a thinner maximum intimal thickness compared with those without fracture (0.27 [0.16–0.38] mm vs. 0.38 [0.23–0.54] mm, p < 0.001). Receiver operating characteristic analysis of maximum intimal thickness for calcium fracture showed an AUC of 0.64 with a cutoff of 0.34 mm. Based on this cutoff, 198 segments were classified as the thin intimal thickness group (≤ 0.34 mm) and 159 as the thick intimal thickness group (> 0.34 mm). Thin intimal thickness was independently associated with calcium fracture (OR = 2.70, 95% CI 1.60–4.56, p < 0.001), after adjusting for calcium angle and minimum calcium thickness. Thin intimal thickness of the superficial calcific sheet was positively associated with calcium fracture after IVL.

  • Open Access

    Evaluation of the Intravascular Ultrasound Calcium Scoring System in Guiding Intravascular Lithotripsy During Percutaneous Coronary Intervention

    by Shun Kitajima, Masaomi Gohbara, Kyoko Hattori, Yohei Hanajima, Katsuhiko Tsutsumi, Hidekuni Kirigaya, Jin Kirigaya, Shinnosuke Kikuchi, Hidefumi Nakahashi, Yuichiro Kimura, et al.

    Background: In Japan, intravascular lithotripsy (IVL) is indicated during percutaneous coronary intervention (PCI) for calcified lesions when the calcium score assessed by intravascular ultrasound (IVUS) or optical coherence tomography (OCT) is ≥3. This study evaluated the effectiveness of IVL in achieving optimal stent expansion in lesions with an OCT calcium score ≥3, regardless of the IVUS calcium score.Methods and Results: We retrospectively compared 26 consecutive PCIs in 23 patients who underwent IVL with pre-PCI OCT or optical frequency domain imaging and simultaneous pre- and post-PCI IVUS with 102 patients who underwent PCI without atherectomy but similar imaging protocols. Of all 128 PCIs, 84 with an OCT calcium score ≥3 and a simultaneous IVUS calcium score ≤2 were analyzed. Stent expansion was measured by IVUS. Among the 84 PCIs included in the analysis, 17 were performed using IVL and 67 were performed without atherectomy or IVL (non-IVL group). Stent expansion at the site of maximum superficial calcium was greater in the IVL than non-IVL group (90.9% vs. 84.6%, respectively; P=0.028). The non-IVL group was independently associated with reduced stent expansion at the site of maximum superficial calcium, even after adjusting for IVUS calcium score components (B=−0.817; P<0.001).Conclusions: Even in calcified lesions with an IVUS calcium score ≤2, IVL was independently associated with favorable stent expansion when the OCT calcium score was ≥3.


  • Intravascular ultrasound surrogate markers for optical coherence tomography calcium score in percutaneous coronary intervention

    by Kyoko Hattori, Masaomi Gohbara, Shun Kitajima, Yohei Hanajima, Katsuhiko Tsutsumi, Hidekuni Kirigaya, Jin Kirigaya, Shinnosuke Kikuchi, Hidefumi Nakahashi, Yuichiro Kimura, et al.


  • Long-term outcomes and operators’ experience in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

    by Kei Takamizawa, Masaomi Gohbara, Yohei Hanajima, Katsuhiko Tsutsumi, Hidekuni Kirigaya, Jin Kirigaya, Hidefumi Nakahashi, Yugo Minamimoto, Yuichiro Kimura, Noriyuki Kawaura, et al.

    Primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) is typically performed by experienced operators. Therefore, the safety of pPCI for STEMI performed by less experienced operators with the support of experienced operators remains unknown. We aimed to investigate the long-term outcomes of pPCI for STEMI performed by less experienced operators with the support of experienced operators. In total, 775 STEMI patients were enrolled and divided into groups according to operator experience in PCI: less experienced (n = 384) and experienced (n = 391) operator groups. Experienced operators were defined as those who had performed > 50 elective PCI procedures per year as the first operator or instructional assistant, whereas less experienced operators were defined as others. When less experienced operators performed the pPCI, experienced operators supported them. The primary endpoint was any cardiovascular event, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and unplanned hospitalization for heart failure. In the propensity score-matched analysis, 324 patients were included in each group. The cumulative incidence of the primary endpoint over a median of 5 years in the less experienced operator group was similar to that in the experienced operator group (15% vs. 18%, P = 0.209). In the multivariate Cox proportional hazards model, there was no excess risk for patients operated upon by less experienced operators for the primary endpoint (adjusted hazard ratio, 0.85; 95% confidence interval, 0.58–1.25; P = 0.417). pPCI for STEMI by less experienced operators did not increase the risk of in-hospital mortality or 5-year long-term cardiovascular events if supported by experienced operators. Graphical abstract


  • Association between evolocumab use and slow progression of aortic valve stenosis

    by Kengo Terasaka, Masaomi Gohbara, Takeru Abe, Tomohiro Yoshii, Yohei Hanajima, Jin Kirigaya, Mutsuo Horii, Shinnosuke Kikuchi, Hidefumi Nakahashi, Kensuke Matsushita, et al.

    No medications have been reported to inhibit the progression of aortic valve stenosis (AS). The present study aimed to investigate whether evolocumab use is related to the slow progression of AS evaluated by serial echocardiography. This was a retrospective observational study from 2017 to 2022 at Yokohama City University Medical Center. Patients aged ≥ 18 with moderate AS were included. Exclusion criteria were (1) mild AS; (2) severe AS defined by maximum aortic valve (AV) velocity ≥ 4.0 m/s; and/or (3) no data of annual follow-up echocardiography. The primary endpoint was the association between evolocumab use and annual changes in the maximum AV-velocity or peak AV-pressure gradient (PG). A total of 57 patients were enrolled: 9 patients treated with evolocumab (evolocumab group), and the other 48 patients assigned to a control group. During a median follow-up of 33 months, the cumulative incidence of AS events (a composite of all-cause death, AV intervention, or unplanned hospitalization for heart failure) was 11% in the evolocumab group and 58% in the control group (P = 0.012). Annual change of maximum AV-velocity or peak AV-PG from the baseline to the next year was 0.02 (− 0.18 to 0.22) m/s per year or 0.60 (− 4.20 to 6.44) mmHg per year in the evolocumab group, whereas it was 0.29 (0.04–0.59) m/s per year or 7.61 (1.46–16.48) mmHg per year in the control group (both P < 0.05). Evolocumab use was associated with slow progression of AS and a low incidence of AS events in patients with moderate AS.


  • Open Access

    Clinical Usefulness of Echocardiographic Measurement of Proximal Aortic Diameter in Early Differentiation Between Type A Acute Aortic Dissection and ST‐Segment–Elevation Myocardial Infarction

    by Jin Kirigaya, Noriaki Iwahashi, Takeru Abe, Masaomi Gohbara, Yohei Hanajima, Mutsuo Horii, Kozo Okada, Yasushi Matsuzawa, Shota Yasuda, Masami Kosuge, et al.

    Background: Contradictions between management modalities of type A acute aortic dissection (TAAAD) and ST‐elevation–myocardial infarction (STEMI) may result in clinical catastrophe. Therefore, we aimed to explore which 2‐dimensional echocardiography (2DE) findings are optimal for differentiating TAAAD from STEMI. Methods and Results: This study included 340 patients with STEMI and 340 patients with TAAAD who underwent 2DE in the emergency department between 2012 and 2021. The proximal ascending aorta (PAA) diameter and other echocardiographic parameters were analyzed. PAA diameters were measured at 4 levels in the parasternal view: Valsalva, the sinotubular junction (STJ), the PAA at 1 cm above the STJ, and the PAA at 2 cm above the STJ. Receiver‐operating characteristic curve analysis showed that Valsalva, STJ, PAA at 1 cm above the STJ, and PAA at 2 cm above the STJ were significant predictors of TAAAD (areas under the curve: 0.777, 0.924, 0.965, and 0.975, respectively; P <0.001) with the respective cutoff values of 39.4, 38.5, 39.8, and 41.2 mm. Multivariable analysis suggested that all 2DE parameters were significant predictors of TAAAD. Among the 2DE parameters examined, the incorporation of PAA at 2 cm above the STJ to clinical indicators exhibited the most significant diagnostic capability (C‐statistics, 0.97; net reclassification improvement, 1.81; integrated discrimination improvement, 0.61). When only TAAAD with coronary malperfusion and STEMI were analyzed, the diagnostic utility of PAA at 1 cm above the STJ was evident (C‐statistics, 0.99; net reclassification improvement, 1.79; integrated discrimination improvement, 0.67), with PAA at 2 cm above the STJ ranking second in diagnostic significance (C‐statistics, 0.99; net reclassification improvement, 1.12; integrated discrimination improvement, 0.66). Conclusions: PAA measurements were the most beneficial for diagnosing TAAAD in all 2DE findings and TAAAD from STEMI.


  • SYNTAX Score and 1-Year Outcomes in the OPTIVUS-Complex PCI Study Multivessel Cohort

    by Masaomi Gohbara, Kiyoshi Hibi, Takeshi Morimoto, Hidekuni Kirigaya, Ko Yamamoto, Koh Ono, Hiroki Shiomi, Masanobu Ohya, Kyohei Yamaji, Hiroki Watanabe, et al.